Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care

Table 3 Medium-throughput targeted sequencing ^Т of GEC patients undergoing curative intent resection demonstrating profound interpatient molecular heterogeneity

Patient	Oncogene	Tumor suppressor
1	HER2 Amp+, SRC Amp+, TOP1 Amp+
2	FGFR2 Amp+	TP53 mt, CDH1 mt
3	SRC Amp+, AURKA Amp+, CCND1 Amp+, CDK4 Amp+, RICTOR Amp+, MDM2 Amp+	CDKN2A/B Loss, ATM mt
4	HER2 Amp+, PIK3CA mt, CDK6 Amp+	TP53 mt, PTEN mt
5	MDM2 Amp+
6	MYCN Amp+	TP53 mt, FANCA Loss
7	PIK3CA mt
8		ARID1A mt, ARID2 mt, Smad2 mt, MLL2 mt
9	HER2 Amp+, PIK3CA mt	TP53 mt
10		CDH1 mt, CDH1 Splice Site mt
11	CCND1 Amp+, EZH2 mt, FGF19 Amp+, FGF3 Amp+, FGF4 Amp+
12		CDH1 Splice Site mt, CDKN2A mt, ARID1A mt, ARID2 mt
13	PIK3CA mt, ERBB3 mt, AXL mt, KDR mt	NF1 mt, ARID1A mt, CREBBP mt, CTCF mt, MLH1 mt
14		ARID1A mt
15	KRAS Amp+, CCNE1 Amp+, MDM4 Amp+	TP53 mt, FBXW7 mt, PTEN mt
16	HER2 Amp+
17	KRAS mt	TP53 mt, CDKN2A mt
18		CDH1 Splice Site mt, LRP1B mt, MLL2 mt
19	Rictor Amp+	TP53 mt, KDM6A splice mt
20	CTNNB1	TP53 mt
21	HER2 mt, ERBB3 mt	TP53 mt (x2), DNMT3A mt, MSH2 mt

Legend: Amp+: Amplified, mt: mutation.
^Т Sequencing performed using Foundation One Platform (first generation – 186 genes), except patients 11–21, who were sequenced on the second generation platform (236 genes).

ISSN: 1756-8722